Articles tagged "Induction therapy"

2018 American Transplant Congress
Basiliximab Induction in Simultaneous Liver-Kidney Transplant
C. Song, X. Luo, L. Pote, S. Strout, D. Segev, N. Desai, A. Gurakar, F. Navqi, J. Garonzik Wang.
The Johns Hopkins Hospital, Baltimore.
Rabbit anti-thymocyte globulin (rATG) is the most common induction agent in renal transplant recipients; however, induction agent selection for SLK recipients is not well described.…
2018 American Transplant Congress
Outcomes Associated with Rabbit Anti-Thymocyte Globulin Induction According to Mg/Kg of Total Body Weight in Kidney Transplant Recipients
A. Brueckner, A. Logan, L. Bowman.
Pharmacy, Tampa General Hospital, Tampa, FL.
Purpose: The optimal dosing weight used for rabbit anti-thymocyte globulin (rATG) induction therapy in transplantation continues to lack a consensus. The impact of alternative dosing…
2018 American Transplant Congress
Novel Low Dosing of Rabbit Antithymocyte Globulin Preserves Excellent Outcomes and Improves the Value of Care in Low Risk Renal Transplantation
J. Dann, W. Ally, M. Bradley, J. Geyston, A. Agarwal.
University of Virginia Health System, Charlottesville, VA.
Elderly and non-sensitized renal transplant patients may benefit from lesser induction immunosuppression. This study evaluates three year clinical outcomes of a low risk renal transplant…
2018 American Transplant Congress
Survey of Rabbit Anti-Thymocyte Globulin Usage for Kidney Transplant Induction Therapy in the United States
K. Foster,¹ A. Dodson,² K. Gutierrez.²
¹Samford University McWhorter School of Pharmacy, Birmingham, AL; ²Comprehensive Transplant Institute, UAB Hospital, Birmingham, AL.
Background: Rabbit anti-thymocyte globulin (rATG) has become the most widely used induction agent in kidney transplantation (KTx) and has recently received FDA approval for this…
2018 American Transplant Congress
The Efficacy and Safety of Rituximab as Induction Therapy in Kidney Transplantation: A Meta-Analysis of Randomized Controlled Trials
X. Wang,¹ J. Chen,² X. Tu,² Y. Qiu,¹ T. Song,¹ T. Lin.¹
¹Department of Urology/Institute of Urology/Organ Transplantation Center, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China; ²West China School of Clinical Medicine, Sichuan University, Chengdu, Sichuan Province, China.
Objectives. This meta-analysis was undertaken to assess the efficacy and safety of rituximab as induction therapy in kidney transplantation.Methods. OVID, Embase, SCI, PubMed and EBSCO…
2018 American Transplant Congress
Rhesus-Specific Anti-Thymocyte Globulin as an Adjuvant to Costimulatory-Blockade-Based Immunotherapy
M. Mulvihill,¹ B. Ezekian,¹ Q. Gao,¹ K. Samy,¹ R. Davis,¹ F. Leopardi,¹ A. Belli,² W. Flores,² A. Buzby,² K. Reimann,² B. Collins,¹ A. Kirk.¹
¹Department of Surgery, Duke University, Durham, NC; ²MassBiologics, University of Massachusetts Medical School, Boston, MA.
Background Belatacept targets de novo alloimmune responses with minimal off target effects in renal transplantation, though adjuvant therapy is required to control costimulation-blockade resistant rejection…
2018 American Transplant Congress
Individualized Immunosuppression through Risk-Stratification in Renal Transplantation Preserves Excellent Outcomes at Three Years
J. Dann, A. Agarwal, M. Bradley, J. Geyston, W. Ally.
University of Virginia Health System, Charlottesville, VA.
Risk-stratification of renal transplant recipients based on immunologic risk factors allows for tailored immunosuppression (IS), but long term follow up is limited. This study evaluates…
2018 American Transplant Congress
Higher Rates of Rejection in HIV-Infected Kidney Transplant Recipients on Ritonavir-Boosted Protease Inhibitors–Three-Year Follow Up
B. Rollins, S. Farouk, G. DeBoccardo, S. Lerner, M. Rana, S. Huprikar, L. Miko, V. Delaney, S. Florman, R. Shapiro.
The Mount Sinai Hospital, New York.
Background: One-year rejection rates in HIV-infected kidney transplant recipients range from 15-40%, compared to overall rejection rates of 10% in HIV-negative patients. Protocols for immunosuppression…
2018 American Transplant Congress
Comparing Outcomes between Induction Immunosuppressive Therapies in Simultaneous Liver/Kidney Transplantation
U. Gautam, T. Reichman, J. Yu, S. Koppu, D. Bandyopadhyay, M. Levy, G. Gupta, L. Kamal.
Virginia Commonwealth University, Richmond, VA.
Introduction: There is no data on the risks and benefits of induction immunosuppression in simultaneous liver/kidney transplant (SLKT) patients.Methods: We analyzed all SLKT performed between…
2018 American Transplant Congress
Cancer Incidence after Kidney Transplantation in Saudi Arabia, Comparing Different Induction Agents
H. AlEid, S. Raza, T. Ali, I. Alahmadi, S. Aleid, D. Broering.
Kidney and Pancreas Transplantation, King Faisal Specialist Hospital, Riyadh, Saudi Arabia.
Cancer incidence varies among different induction agents and different population. We aim to compare the incidence of cancer post kidney transplantation among different induction agents…